Incidence and Prevalence of Patients with Myelodysplastic Syndromes (MDS) in Dusseldorf 1996-2005.

被引：0
|
作者：
Neukirchen, Judith [1 ]
Schoonen, W. Marieke [2 ]
Aul, Carlo [3 ]
Haas, Rainer [1 ]
Gattermann, Norbert [1 ]
Germing, Ulrich [1 ]
机构：
[1] Univ Dusseldorf, Dusseldorf, Germany
[2] Amgen Ltd, Cambridge, England
[3] St Johannes Hosp, Med Clin 2, Duisburg, Germany
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：705 / 706
页数：2
相关论文
共 50 条
  • [21] Combination of thalidomide and Enbrel for the treatment of patients with myelodysplastic syndromes (MDS).
    Raza, A
    Dutt, D
    Lisak, L
    Dean, L
    Fantroy, L
    Gezer, S
    Syed, E
    Goldberg, C
    Loew, J
    Hsu, WT
    Venugopal, P
    BLOOD, 2001, 98 (11) : 273B - 274B
  • [22] Prevalence and complications associated with off-label use of lenalidomide in older patients with myelodysplastic syndromes (MDS).
    Brunner, Andrew Mark
    Weng, Shicheng
    Cronin, Angel M.
    Fathi, Amir Tahmasb
    Stone, Richard M.
    Graubert, Timothy A.
    Steensma, David P.
    Abel, Gregory A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [23] Diagnostic procedures and treatment of patients with Myelodysplastic Syndromes (MDS) - update of the outpatient MDS registry
    Schmitz, S.
    Boettger, I
    Sauer, A.
    Buschmann, D.
    Germing, U.
    Severin, K.
    Steinmetz, H. T.
    ONKOLOGIE, 2013, 36 : 242 - 242
  • [24] Improvement in cytopenias of patients with myelodysplastic syndromes (MDS) in response to thalidomide
    Raza, A
    Lisak, L
    Little, L
    Andrews, C
    Meyer, P
    Ekbal, M
    Venugopal, P
    EXPERIMENTAL HEMATOLOGY, 2000, 28 (07) : 103 - 104
  • [25] THE IMPACT OF MYELODYSPLASTIC SYNDROMES (MDS) ON THE MENTAL HEALTH OF PATIENTS AND CAREGIVERS
    Scheurmeyer, Isabel
    Hughes, Mary
    Sloan, Erika
    LeBlanc, Thomas
    Houk, Alice
    Sirewu, Nyaradzo
    ONCOLOGY NURSING FORUM, 2024, 51 (02)
  • [26] Incidence of myelodysplastic syndromes (MDS) in the geographically defined area of south-western Greece
    Schoonen, W.
    Aagnes, B.
    Bray, F.
    Hansen, S.
    Fryzek, J.
    Weiderpass, E.
    LEUKEMIA RESEARCH, 2009, 33 : S64 - S65
  • [27] Treatment Outcome of Patients with Myelodysplastic Syndromes (MDS) in Regular Care: Incidence of IPSS Risk Groups and Different Therapies in the German Outpatient MDS Registry
    Steinmetz, H. Tilman
    Boettger, Isolde
    Lathan, Bernd
    Sauer, Annette
    Moorahrend, Enno
    Severin, Kai
    Germing, Ulrich
    Schmitz, Stephan
    Gattermann, Norbert
    BLOOD, 2014, 124 (21)
  • [28] A Novel Prognostic Model in Heavily Treated Patients with Myelodysplastic Syndromes (MDS)
    Nazha, Aziz
    Seastone, David J.
    Radivoyevitch, Tomas
    Gerds, Aaron T.
    Mukherjee, Sudipto
    Carraway, Hetty E.
    Advani, Anjali S.
    Kalaycio, Matt E.
    Rupp, Gina
    Colaluka, Kristin
    Hobson, Sean
    Maciejewski, Jaroslaw P.
    Sekeres, Mikkael A.
    BLOOD, 2014, 124 (21)
  • [29] COMBINATION OF ORAL RIGOSERTIB AND INJECTABLE AZACITIDINE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
    Navada, S.
    Garcia-Manero, G.
    Hearn, K.
    Odchimar-Reissig, R.
    Demakos, E.
    Fenaux, P.
    Petrone, M.
    Zbyszewski, P.
    Fruchtman, S.
    Silverman, L.
    LEUKEMIA RESEARCH, 2017, 55 : S30 - S30
  • [30] MEGAKARYOCYTOPOIESIS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) WITH AND WITHOUT DEL(5+)
    PODOLAKDAWIDZIAK, M
    GEDDES, D
    BOWEN, D
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1990, 45 (02) : 115 - 116
12345